In breast and certain other cancers, receptor tyrosine kinases, including the insulin-like growth factor I receptor (IGF-IR), play an important role in promoting the oncogenic process. The IGF-IR is therefore an important target for developing new anti-breast cancer therapies. An initial screening of a chemical library against the IGF-IR in breast cancer cells identified a diaryl urea compound as a potent inhibitor of IGF-IR signaling. This class of compounds has not been studied as inhibitors of the IGF-IR. We studied the effectiveness of one diaryl urea compound, PQ401, at antagonizing IGF-IR signaling and inhibiting breast cancer cell growth in culture and in vivo. PQ401 inhibited autophosphorylation of the IGF-IR in cultured human MCF-7 cells with an IC50 of 12 micromol/L and autophosphorylation of the isolated kinase domain of the IGF-IR with an IC50 <1 micromol/L. In addition, PQ401 inhibited the growth of cultured breast cancer cells in serum at 10 micromol/L. PQ401 was even more effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 micromol/L). Treatment of MCF-7 cells with PQ401 was associated with a decrease in IGF-I-mediated signaling through the Akt antiapoptotic pathway. Twenty-four hours of treatment with 15 micromol/L PQ401 induced caspase-mediated apoptosis. In vivo, treatment with PQ401 (i.p. injection thrice a week) reduced the growth rate of MCNeuA cells implanted into mice. These studies indicate that diaryl urea compounds are potential new agents to test in the treatment of breast and other IGF-I-sensitive cancers.
"Several of these drugs are currently in Phase I trials as single agents or in combination with chemotherapy. [7-11] A critical aspect in the design of these trials has been the selection of appropriate surrogate end-points of treatment response. In addition to measuring objective tumor response, a few studies have incorporated serum measurement of IGFBP-3 as a biomarker of disease progression. "
[Show abstract][Hide abstract] ABSTRACT: Different Insulin-like Growth Factor Binding Proteins (IGFBPs) have been investigated as potential biomarkers in several types of tumors. In this study, we examined both IGFBP-3 and -4 levels in tissues and sera of melanoma patients representing different stages of melanoma progression.
The study cohort consisted of 132 melanoma patients (primary, n = 72; metastatic, n = 60; 64 Male, 68 Female; Median Age = 56) prospectively enrolled in the New York University School of Medicine Interdisciplinary Melanoma Cooperative Group (NYU IMCG) between August 2002 and December 2006. We assessed tumor-expression and circulating sera levels of IGFBP-3 and -4 using immunohistochemistry and ELISA assays. Correlations with clinicopathologic parameters were examined using Wilcoxon rank-sum tests and Spearman-rank correlation coefficients.
Median IGFBP-4 tumor expression was significantly greater in primary versus metastatic patients (70% versus 10%, p = 0.01) A trend for greater median IGFBP-3 sera concentration was observed in metastatic versus primary patients (4.9 microg/ml vs. 3.4 microg/ml, respectively, p = 0.09). However, sera levels fell within a normal range for IGFBP-3. Neither IGFBP-3 nor -4 correlated with survival in this subset of patients.
Decreased IGFBP-4 tumor expression might be a step in the progression from primary to metastatic melanoma. Our data lend support to a recently-described novel tumor suppressor role of secreting IGFBPs in melanoma. However, data do not support the clinical utility of measuring levels of IGFBP-3 and -4 in sera of melanoma patients.
Journal of Translational Medicine 12/2008; 6(1):70. DOI:10.1186/1479-5876-6-70 · 3.93 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The insulin-like family is not only an important regulatory factor for animal growth, development, and metabolism, but also a mediator for initiating growth activity of growth hormone. It plays an important role in transferring transmembrane information and regulating cell function by binding to tyrosine kinase receptors (insulin receptors). To better understand the role of insulin-related peptide receptor (Pfirr) on the developmental regulation in Pinctada fucata, 5.326 kb encoding cDNAs for Pfirr have been cloned and functionally characterized. Pfirr displays significant homologies to Crassostrea gigas, and exhibits all the typical features of insulin receptors and tyrosine kinase domain structure, both of which are typical for the protein family sharing high similarity to other orthologs. Real-time PCR analyses show that Pfirr widely expresses in tissues and developmental stages of P. fucata. Expression of Pfirr mRNAs at different developmental stages (polar body stage, the trocophore stage and D-shaped larva stage) following treatment with agonist IGF-I(1, 2, 4 and 8 μM/L) and antagonist PQ401 (5, 15, 25, 50 and 100 μM/L) indicated that Pfirr may be involved in regulating the development of embryos in P. fucata. These results clearly demonstrate Pfirr is involved in regulating developmental process in P. fucata.
Aquaculture 09/2013; s 408–409:118–127. DOI:10.1016/j.aquaculture.2013.05.038 · 1.88 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: A series of substituted N-(quinolin-4-yl)ethanediamine phenyl urea derivatives of biological interest were prepared by sequential quinoline synthesis, chlorination, and substitution reaction followed by reaction of resulting amine with different aryl isocyanates. All synthesized compounds (1–13) were screened for their pro-inflammatory cytokines (TNF-α and IL-6) and antimicrobial activity (antibacterial and antifungal). Biological activity evaluation study revealed that among all the compounds screened, compounds 4 and 6 were found to have promising anti-inflammatory activity (up to 78–71 % TNF-α and 96–90 % IL-6 inhibitory activity) at a higher concentration of 10 μM with reference to standard dexamethasone (72 % TNF-α and 86 % IL-6 inhibitory activities at 1 μM). Compounds 6, 8, 10, and 11 overall exhibited promising antimicrobial activity at MIC values ranging from 10 to 30 μg/mL against all the selected pathogenic bacteria and fungi.
Medicinal Chemistry Research 03/2012; 22(3). DOI:10.1007/s00044-012-0144-5 · 1.40 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.